Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.6K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Directing Effect of Substituents: meta-Directing Groups01:09

Directing Effect of Substituents: meta-Directing Groups

6.0K
Substituents on the benzene ring that direct an incoming electrophile to undergo substitution at the meta position are called meta directors. All meta directors either have a positive charge on the atom directly bonded to the ring or a partial positive charge. These groups function by withdrawing electrons from the ring through inductive and resonance effects. Consider the carbocation intermediates formed upon the addition of an electrophile on nitrobenzene at the...
6.0K
Hormonal Regulation01:33

Hormonal Regulation

36.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival.

European heart journal open·2026
Same author

Drug-Coated Balloons Versus Drug-Eluting Stents Following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-analysis.

The American journal of cardiology·2026
Same author

Impact of baseline tricuspid regurgitation on outcomes after mitral transcatheter edge-to-edge repair: A systematic review and meta-analysis.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Immediate Aspirin Discontinuation Following Percutaneous Coronary Intervention for Acute Coronary Syndromes.

The American journal of cardiology·2026
Same author

Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: a systematic review and meta-analysis.

Coronary artery disease·2026
Same author

Can the FIB-4 index predict mortality in patients with coronary artery disease? A systematic review and meta-analysis.

Current problems in cardiology·2026

Related Experiment Video

Updated: Feb 10, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.6K

A Bayesian Meta-Analysis of Renin-Angiotensin System Inhibitors Following TAVR.

Vinícius Martins Rodrigues Oliveira1,2, Lucas M Barbosa3,4, Pedro Antônio de Sousa5

  • 1Federal University of Goiás, Goiânia, Brazil.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|February 9, 2026
PubMed
Summary

Renin-angiotensin system (RAS) inhibitors after transcatheter aortic valve replacement (TAVR) significantly reduce mortality and heart failure readmissions. This therapy shows a high probability of improving cardiovascular outcomes in patients with aortic stenosis.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K
Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI
06:26

Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI

Published on: November 27, 2019

77.7K

Related Experiment Videos

Last Updated: Feb 10, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.6K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K
Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI
06:26

Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI

Published on: November 27, 2019

77.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Interventions

Background:

  • Aortic stenosis causes detrimental left ventricular remodeling, increasing heart failure risk.
  • Transcatheter aortic valve replacement (TAVR) improves outcomes but persistent complications remain.
  • Renin-angiotensin system (RAS) inhibitors may offer protective effects post-TAVR.

Purpose of the Study:

  • To assess the impact of RAS inhibitor therapy on clinical outcomes following TAVR.
  • To provide evidence for optimizing post-TAVR management strategies.

Main Methods:

  • Systematic review and Bayesian meta-analysis of 12 studies with 35,988 patients.
  • Compared RAS inhibitor use versus non-use in patients undergoing TAVR.
  • Estimated odds ratios and credible intervals using a Bayesian random-effects model.

Main Results:

  • RAS inhibitor use was linked to a 79.4% probability of reduced all-cause mortality and 99.5% for cardiovascular mortality.
  • A 54% probability of reduced heart failure hospitalization was observed.
  • Negligible impact on myocardial infarction rates was found.

Conclusions:

  • RAS inhibitor therapy following TAVR is associated with significantly reduced mortality.
  • RAS inhibitor use demonstrates a positive association with decreased heart failure readmissions.